Cargando…

Physician-pharmacist agreement about off-label use of medications in private clinical settings in Baghdad, Iraq

OBJECTIVE: 1) To evaluate the relationship between physician-pharmacist agreement about the off-label drug use and 2) and to identify the most common off-label medication category/indications and prescriber clinical disciplines in private settings in Baghdad area, Iraq METHODS: This study evaluated...

Descripción completa

Detalles Bibliográficos
Autores principales: Hussain, Saad A., Abbas, Ashwaq N., Alhadad, Hasan A., Al-Jumaili, Ali A., Abdulrahman, Zainab S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Centro de Investigaciones y Publicaciones Farmaceuticas 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5597808/
https://www.ncbi.nlm.nih.gov/pubmed/28943980
http://dx.doi.org/10.18549/PharmPract.2017.03.979
_version_ 1783263777393737728
author Hussain, Saad A.
Abbas, Ashwaq N.
Alhadad, Hasan A.
Al-Jumaili, Ali A.
Abdulrahman, Zainab S.
author_facet Hussain, Saad A.
Abbas, Ashwaq N.
Alhadad, Hasan A.
Al-Jumaili, Ali A.
Abdulrahman, Zainab S.
author_sort Hussain, Saad A.
collection PubMed
description OBJECTIVE: 1) To evaluate the relationship between physician-pharmacist agreement about the off-label drug use and 2) and to identify the most common off-label medication category/indications and prescriber clinical disciplines in private settings in Baghdad area, Iraq METHODS: This study evaluated 980 off-label use requests in the private clinical settings within Baghdad area, Iraq from October 2013 to September 2015. The efficacy, safety, and convenience of each drug request and its alternative options were evaluated according to the patient health and demographic characteristics and standard guidelines. RESULTS: Of the 980 physician off-label requests, only 22.7% were approved by the pharmacists. Rheumatology and Nephrology accounted for the highest ratio of off-label use requests for adults (30.3% and 26.3%). The pharmacist rejection ratio of off-label use was comparable between the two groups (p>0.05). Most of the issued requests were attributed either to unapproved indication or to combination of more than one drug (38% and 35.3%). A low acceptance rate was reported in the requests issued for treatment in different clinical lines to the authorized one (11.9%). The lowest rate of acceptance was reported in the requests that had very low evidence level (9.1%). The mostly prescribed medications were musculoskeletal agents (28.9%). Finally, 78.2% of the requests came from clinical branches for adults. Although the agreement rate for requests in adults was higher than that in pediatrics, the two rates were not significantly different. CONCLUSION: Community pharmacists should effectively take responsibility for assessing off-label drug requests in Iraqi private settings. The quality of evidence does not represent the major factor influencing the approval rate of off-label drug use. The availability of safer and/or affordable alternatives and prescribing for a different patient age category highly impacted the pharmacists’ approval rate.
format Online
Article
Text
id pubmed-5597808
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Centro de Investigaciones y Publicaciones Farmaceuticas
record_format MEDLINE/PubMed
spelling pubmed-55978082017-09-22 Physician-pharmacist agreement about off-label use of medications in private clinical settings in Baghdad, Iraq Hussain, Saad A. Abbas, Ashwaq N. Alhadad, Hasan A. Al-Jumaili, Ali A. Abdulrahman, Zainab S. Pharm Pract (Granada) Original Research OBJECTIVE: 1) To evaluate the relationship between physician-pharmacist agreement about the off-label drug use and 2) and to identify the most common off-label medication category/indications and prescriber clinical disciplines in private settings in Baghdad area, Iraq METHODS: This study evaluated 980 off-label use requests in the private clinical settings within Baghdad area, Iraq from October 2013 to September 2015. The efficacy, safety, and convenience of each drug request and its alternative options were evaluated according to the patient health and demographic characteristics and standard guidelines. RESULTS: Of the 980 physician off-label requests, only 22.7% were approved by the pharmacists. Rheumatology and Nephrology accounted for the highest ratio of off-label use requests for adults (30.3% and 26.3%). The pharmacist rejection ratio of off-label use was comparable between the two groups (p>0.05). Most of the issued requests were attributed either to unapproved indication or to combination of more than one drug (38% and 35.3%). A low acceptance rate was reported in the requests issued for treatment in different clinical lines to the authorized one (11.9%). The lowest rate of acceptance was reported in the requests that had very low evidence level (9.1%). The mostly prescribed medications were musculoskeletal agents (28.9%). Finally, 78.2% of the requests came from clinical branches for adults. Although the agreement rate for requests in adults was higher than that in pediatrics, the two rates were not significantly different. CONCLUSION: Community pharmacists should effectively take responsibility for assessing off-label drug requests in Iraqi private settings. The quality of evidence does not represent the major factor influencing the approval rate of off-label drug use. The availability of safer and/or affordable alternatives and prescribing for a different patient age category highly impacted the pharmacists’ approval rate. Centro de Investigaciones y Publicaciones Farmaceuticas 2017 2017-08-20 /pmc/articles/PMC5597808/ /pubmed/28943980 http://dx.doi.org/10.18549/PharmPract.2017.03.979 Text en Copyright: © Pharmacy Practice http://creativecommons.org/licenses/by-nc-nd/3.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY-NC-ND 3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Original Research
Hussain, Saad A.
Abbas, Ashwaq N.
Alhadad, Hasan A.
Al-Jumaili, Ali A.
Abdulrahman, Zainab S.
Physician-pharmacist agreement about off-label use of medications in private clinical settings in Baghdad, Iraq
title Physician-pharmacist agreement about off-label use of medications in private clinical settings in Baghdad, Iraq
title_full Physician-pharmacist agreement about off-label use of medications in private clinical settings in Baghdad, Iraq
title_fullStr Physician-pharmacist agreement about off-label use of medications in private clinical settings in Baghdad, Iraq
title_full_unstemmed Physician-pharmacist agreement about off-label use of medications in private clinical settings in Baghdad, Iraq
title_short Physician-pharmacist agreement about off-label use of medications in private clinical settings in Baghdad, Iraq
title_sort physician-pharmacist agreement about off-label use of medications in private clinical settings in baghdad, iraq
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5597808/
https://www.ncbi.nlm.nih.gov/pubmed/28943980
http://dx.doi.org/10.18549/PharmPract.2017.03.979
work_keys_str_mv AT hussainsaada physicianpharmacistagreementaboutofflabeluseofmedicationsinprivateclinicalsettingsinbaghdadiraq
AT abbasashwaqn physicianpharmacistagreementaboutofflabeluseofmedicationsinprivateclinicalsettingsinbaghdadiraq
AT alhadadhasana physicianpharmacistagreementaboutofflabeluseofmedicationsinprivateclinicalsettingsinbaghdadiraq
AT aljumailialia physicianpharmacistagreementaboutofflabeluseofmedicationsinprivateclinicalsettingsinbaghdadiraq
AT abdulrahmanzainabs physicianpharmacistagreementaboutofflabeluseofmedicationsinprivateclinicalsettingsinbaghdadiraq